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In astrocyte-enriched cultures of the rat cerebral cortex the Ca2+ lonophore A23 187 provoked the break- 
down of inositol phospholipids, the liberation of arachidonic acid and the release of prostaglandins E2. Fzll, 
I? and thromboxane AZ. However, agonists for receptors also coupled to inositol phospholipid metabolism 
in these cells failed to produce an increase in the release of both arachidonic acid and eicosanoids. Results 
suggest that the A23 187-stimulated release of arachidonic acid and eicosanoids is caused by a phospholipase 
AZ-mediated attack on lipids other than the inositol phospholipids. Moreover, receptors linked to inositol 
lipid turnover are not involved in the control of eicosanoid release from astrocytes. 
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1. INTRODUCTION 
Eicosanoids have profound effects in the CNS 
where they appear to be involved in the modula- 
tion of behaviour, blood flow and neurotransmis- 
sion [l]. It has recently been shown that at least 
one CNS cell type, the astroglia, possesses the 
capacity to synthesise and release these agents 
[2-51. The close proximity of astrocytes to both 
neurons and the microvasculature in vivo suggests 
that eicosanoids released from these cells may play 
an important role in regulating a variety of neural 
functions. Consequently it is important that we 
understand the mechanisms involved in astroglial 
eicosanoid formation and the nature of the signals 
which control their release. 
Recently, much attention has focused on the 
metabolism of the inositol phospholipids and the 
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role played by their breakdown products in in- 
tracellular signal transduction [6-81. However, 
these lipids also contain arachidonic acid (AA), the 
precursor of eicosanoid synthesis, and it has been 
proposed that their metabolism in response to a 
suitable stimulus may liberate AA for eicosanoid 
production [6,8]. We and others have demon- 
strated that eicosanoid release from astrocytes in 
primary culture can be stimulated by the Ca2+ 
ionophore A23187 [4,5]. Moreover, by measuring 
the accumulation of intracellular inositol phos- 
phates we have also shown that A23 187 induces a 
Ca’+-dependent breakdown of inositol phos- 
pholipids in these cells [9]. Our aim, therefore, was 
to examine more closely the ionophore-stimulated 
metabolism of the inositol phospholipids and to 
determine whether this process is linked in some 
way to eicosanoid formation. In addition, we 
wished to establish whether other agents, such as 
agonists for receptors which are also coupled to in- 
ositol lipid turnover [9,10], are similarly involved 
in regulating astrocyte eicosanoid production. 
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2. MATERIALS AND METHODS 
Astrocyte-enriched cell cultures of the newborn 
rat cerebral cortex were prepared and maintained 
as described [lo, 111. Cells were seeded onto either 
60 mm diameter dishes or 24-well plates and grown 
to confluence (14-18 days in vitro). Im- 
munocytochemical characterisation of these 
cultures revealed that 90-95% of the cells were 
labelled with GFAP showing them to be 
astrocytes. 
Cultures in 60 mm dishes were prelabelled for 
24 h with 1 &i/ml myo-[3H]inositol (15 Ci/ 
mmol, Amersham, final concentration 1OpM) to 
achieve maximum labelling of lipids [9]. The 
stimulus-induced formation of total [3H]inositol 
phosphates over a 60 min incubation period in the 
presence of 5 mM Li+ was assessed as described 
[9]. In some experiments an analysis of the in- 
dividual [3H]inositol phosphates formed during 
short exposure periods (5 s-10 min) was under- 
taken. These incubations were carried out in the 
absence of Li+ and the material from four cultures 
pooled for each determination. The column 
separation of [3H]inositol trisphosphate (IP3), 
bisphosphate (IP$ and monophosphate (IPr) was 
performed by the method of Brown et al. [ 121. The 
A23187-evoked change in the incorporation of 
[3H]inositol into individual inositol lipids was 
determined by separation of the labelled lipids by 
thin-layer chromatography [ 131. The material 
from two cultures was pooled and applied to 
chromatography plates together with lipid stan- 
dards obtained from Sigma. The Rf values for each 
lipid were as follows: phosphatidylinositol (PI, 
0.45), phosphatidylinositol 4-phosphate (PIP, 
0.25) and phosphatidylinositol 4,5-bisphosphate 
(PIP& 0.19). 
Cultures in 24-well plates were used to determine 
either the liberation of 14C from cells prelabelled 
with [r4C]AA or the release of eicosanoids. For the 
former, cultures were labelled for 18 h with 
0.1 &i/ml [14C]AA (59.6 mCi/mmol, Amer- 
sham) which resulted in approx. 20% of the 
radiolabel being incorporated. Cultures were 
washed twice with Earles balanced salt solution 
(EBSS) prior to incubation for 30 min with either 
A23187 or other agents. The r4C released into the 
incubation medium was determined by liquid scin- 
tillation counting. In the latter experiments, 
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cultures were washed with EBSS prior to a 30 min 
exposure to a stimulus. The incubation medium 
was collected, extracted with double distilled ethyl 
acetate and the presence of eicosanoids detected by 
radioimmunoassay. Four eicosanoids were assayed 
for using antisera (Cape11 Laboratories) of high 
serological specificity against prostaglandins EZ 
(PGEz), Fh (PGFh), 6-oxo-prostaglandins Fr, 
(B-oxo-PGFi,) and thromboxane BZ (TXBz), the 
latter being the stable metabolites of prostaglandin 
12 (PGI2) and thromboxane AZ (TXAz), respective- 
ly. Labelled and unlabelled eicosanoids were pur- 
chased from NEN and Sigma, respectively, and 
assays were carried out according to protocols sup- 
plied by Cape11 Laboratories as described [14]. 
3. RESULTS AND DISCUSSION 
A23187 stimulated the liberation of 14C from 
cells prelabelled with [14C]AA and the accumula- 
tion of [3H]inositol phosphates in cells prelabelled 
with [3H]inositol in a dose-dependent manner 
(fig.1). Maximal effects for these responses were 
obtained with 1OpM A23187 and represented 
4-5-fold increas.es over basal. Four eicosanoids 
were assayed for and detected in the conditioned 
medium. The dose-response curve for A23187- 
stimulated release of TXA2 is shown in fig. 1, 
similar curves were obtained for PGE2, PGFt, and 
PGI2. Again maximal TXA2 release was obtained 
-LOG 1MI A23187 
Fig. 1. Concentration-dependence of A23 187-stimulated 
release of TXA2 (A), 14C liberation ( n ) and [3H]inositol 
phosphate accumulation (0) in astrocyte-enriched 
cultures. Values are means (SE < 15%) from 4-6 
determinations. 
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Table 1 
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Time course of A23187-evoked changes in the recovery of ‘H in inositol, inositol phospholipids and inositol phosphates 
Incubation 
time 
Inositol PI 
3H recovered (dpm x lo-‘) 
PIP PIP* IPI IPZ IP3 
0 85395.2 + 1526.4 2128.7 rt 68.2 15.6 + 2.7 14.7 + 4.0 4.6 + 0.6 11.0 f 1.7 3.4 k 0.8 
SS 61112.8 f 6359.8a 1732.1 + 160.4a 30.5 f 4.2a 12.7 + 1.4 6.0 + 0.6” 17.5 f 2.4a 4.8 + 1.1 
30 s 69707.2 + 3919.2a 1834.2 + 187.2 25.9 + 2.7a 19.4 + 3.7 6.8 + 0.8= 21.8 + 3.3a 5.3 f 0.9 
60 s 55041.6 f 6105.0” 1703.3 f 107.8” 26.0 + 2.7a 13.2 + 4.7 7.3 + 0.6= 18.3 f l.8a 4.3 f 0.3 
10 min 60686.4 f 6095.4a 1765.5 + 108.1a 26.9 + 3.3a 10.6.2 3.3 14.9 f 0.9” 20.9 + 1.8” 3.8 f 0.4 
a Significantly different from results at zero time (P < 0.05) by Mann-Whitney U-test 
Astrocyte-enriched cultures were prelabelled with [3H]inositol then exposed to A23187 (5 PM) for the periods indicated. 
Values are means rt SE from 4 determinations 
with 10pM ionophore and corresponded to a 
15-fold increase over basal levels. A23 187 ap- 
peared to be more effective (EC50 0.5 ,uM) in pro- 
moting eicosanoid release than in liberating either 
14C (ECso 1.5 PM) or the accumulation of [3H]in- 
ositol phosphates (EC50 2 PM). PGE2 was found to 
be the most abundant eicosanoid released followed 
by PGFh and TXA2 which were released in almost 
equal amounts. Relatively little PGI2 was found in 
the conditioned medium due to the fact that it is 
synthesised largely in meningeal fibroblasts only a 
small population (5-10%) of which contaminate 
our astrocyte cultures [5]. The other eicosanoids 
were derived entirely from the astrocytes in these 
cultures (Jeremy et al., unpublished). 
The Ca2+ ionophore A23 187 clearly promotes 
the breakdown of inositol phospholipids in 
astrocytes. Previous studies have shown this 
response to be entirely dependent on the presence 
of extracellular Ca2+ [9], suggesting the involve- 
ment of a Ca2+ requiring phospholipase. To deter- 
mine which inositol lipids were metabolised in 
response to A23 187 treatment we examined the 
change in labelling of the lipids and the accumula- 
tion of their labelled breakdown products (IPs, IP2 
and IPi). Table 1 shows that in control cultures 
prelabelled with [3H]inositol for 24 h, the bulk 
(98%) of the label was incorporated into PI, the re- 
mainder being equally distributed in the 
phosphoinositides PIP and PIP2. Incubation with 
A23187 produced no marked or consistent change 
in either the labelling of PIP2 or the accumulation 
of IPs in these cells (table 1). However, there did 
appear to be an increase in the turnover of PIP. 
This was characterised by a rapid and sustained in- 
crease in both the accumulation of IP2 and the 
recovery of ‘H in PIP. There was also a small 
(20-30%) but significant loss of label from PI and 
the pool of free inositol (table 1) which may have 
been the result of the need to replenish the pool of 
PIP. However, a direct A23187-induced break- 
down of PI cannot be excluded because even after 
a 5 s incubation period a significant increase in IPr 
accumulation was evident. 
The finding that A23187 does not affect the 
metabolism of PIP2 but primarily attacks PIP is in 
agreement with previous studies performed on 
other tissues [15,16]. These data confirm that the 
phospholipase C-mediated breakdown of PIP2 is 
not dependent on an increase in intracellular Ca’+. 
Moreover, they also suggest hat the 14C liberated 
from [‘4C]AA-labelled astrocytes was not the 
result of diacylglycerol formation from this lipid. 
Nonetheless, these results do not rule out the 
possibility that AA may be liberated from either 
PIP and/or PI via the activation of a 
Ca2+-dependent phospholipase C [ 171. 
In a number of tissues activation of muscarinic 
and al-adrenergic receptors leads to changes in the 
synthesis and release of eicosanoids [ 1,18-201. 
Astrocytes also possess these receptors and they 
are coupled to membrane inositol phospholipids 
[9,10]. However, the results presented in table 2 
clearly show that although agonists for these recep- 
tors produced large increases in the accumulation 
of [3H]inositol phosphates they were without effect 
75 
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Table 2 
Effect of A23187 and receptor agonists on [3H]inositol phosphate 
accumulation, [14C]AA liberation and TXAz release 
Additions [3H]Inositol 
phosphates 
(dpm) 
[14C]AA TXAz 
(dpm) (ngiml) 
None 1656 * 133 5226 + 471 2.5 * 0.1 
A23187 5825 + 152 28986 + 5211 28.0 f 0.6 
Carbachol 6877 I!I 236 4455 + 102 3.4 + 0.6 
Noradrenaline 11864 + 1611 4305 2 45 2.2 * 0.2 
Astrocyte-enriched cultures were prelabelled with either 
[3H]inositol or [ 14C]AA then incubated with 10 pM A23 187, 1 mM 
carbachol or 1 mM noradrenaline for 60 min (inositol phosphates) 
or 30 min (AA and TXAZ release). Values are means + SE from 
4-6 determinations 
Table 3 
Effect of mepacrine on A23187-evoked [3H]inositol 
phosphate accumulation and TXA2 release 
Additions [3H]Inositol 
phosphates 
(dpm) 
TXAz 
(ngiml) 
None 1406 + 71 6.2 f 0.2 
A23187 7102 + 460 40.0 + 1.4 
A23187 + mepacrine 6427 + 60 14.6 + 0.4 
Astrocyte-enriched cultures were exposed to 10 pM 
A23187 for 60 min in the presence or absence of 10 PM 
mepacrine. Values are means f SE from 4 
determinations 
on either the liberation of 14C from [14C]AA- 
labelled cultures or the release of TXA2. In addi- 
tion, whether they were used in combination or 
with a submaximal dose of A23187, no agonist- 
induced change in the latter two responses was 
observed (not shown). Work carried out on both a 
glioma cell line and on primary astrocytes shows 
that agonists such as those used here do liberate 
AA from lipids although the response is very tran- 
sient and occurred inside the cell only [21,22]. 
These authors also reported the generation briefly 
of an unidentified lipoxygenase metabolite, but the 
levels of PC& PGFh,, PGE2 and PGD2 remained 
unchanged. Our previous studies have shown that 
receptor activation induces the breakdown of 
PIP2, however, a direct Ca2+-dependent break- 
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down of PIP and/or PI was also suggested [9]. It 
would seem therefore that any AA liberated from 
these lipids in the form of diacylglycerol was 
recycled via phosphatidate and not used for 
eicosanoid synthesis. In this regard our data are in 
agreement with other studies on synaptosomes [23] 
and GH3 pituitary cells [24]. 
These findings raise the possibility that even in 
response to treatment with A23187, the inositol 
phospholipids are not the source of AA for 
eicosanoid synthesis in astrocytes. It is generally 
accepted that the metabolism of these lipids is 
mediated by phospholipase C although it has been 
suggested that PI may also undergo attack by 
phospholipase AZ [25]. Table 3 shows that whereas 
A23187-stimulated [3H]inositol phosphate ac- 
cumulation was unchanged, the ionophore-evoked 
increase in TXA2 release was markedly reduced 
(-70%) by mepacrine an apparently selective in- 
hibitor of phospholipase AZ [26]. We interpret 
these results as indicating that eicosanoid release 
from astrocytes in response to A23 187 is the result 
of a phospholipase AZ-mediated attack not on 
inositol phospholipids but on other AA-containing 
lipids such as phosphatidylcholine and/or 
phosphatidylethanolamine as appears to be the 
case in many other cells [24,27]. 
In conclusion, the use of A23187 has revealed 
that astrocytes have the ability to mobilise AA and 
to synthesise and release eicosanoids. It would ap- 
pear that although the ionophore provokes the 
metabolism of inositol phospholipids these do not 
Volume 211, number 1 FEBSLETTERS January 1987 
constitute the source of AA for eicosanoid syn- 
thesis. Moreover, agonists for receptors which also 
induce inositol lipid breakdown are without effect 
on either AA or eicosanoid release, any 
diacylglycerol liberated upon stimulation is prob- 
ably recycled. Thus, the physiological control 
mechanisms which regulate astrocyte eicosanoid 
formation remain to be resolved. 
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